The Europe hyaluronic acid-based dermal fillers market size was exhibited at USD 1.17 billion in 2023 and is projected to hit around USD 2.85 billion by 2033, growing at a CAGR of 9.3% during the forecast period 2024 to 2033.
Report Coverage | Details |
Market Size in 2024 | USD 1.28 Billion |
Market Size by 2033 | USD 2.85 Billion |
Growth Rate From 2024 to 2033 | CAGR of 9.3% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Product, Application, Country |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Country scope | UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway |
Key Companies Profiled | Allergan; Galderma Laboratories; Merz Pharma; Genzym corporation; Medicis Pharmaceutical (Bausch Health); Inamed Corporation; Laboratoires VIVACY; Bioxis Pharmaceuticals |
Growing social media influence and increasing geriatric population are some of the factors contributing to the growth of the market. The market is expected to further grow due to the rising medical tourism and an increase in the number of aesthetic procedures around the globe.
The number of cosmetic clinics in nations like France has increased, helping the Europe industry expand. According to the International Society of Aesthetic Plastic Surgery (ISAPS), in 2016, a total number of 227,307 nonsurgical procedures were performed in France, of which 120,156 were hyaluronic acid procedures, which is the second most preferred noninvasive procedure. Market participants offer cutting-edge items to boost treatment effectiveness and gain a bigger market share. In Germany, Belotero Lips was introduced by Merz in 2018 for treating perioral wrinkles and lip augmentation.
With changing demographics, procedures, and products, dermatologists and physicians can customize therapies or procedures for individual patients. They opt for a combination of products for better outcomes and patient satisfaction. Botulinum toxin and hyaluronic acid dermal fillers are becoming more popular for wrinkle treatment due to increased awareness of the desirable results, ease of performing these procedures, shorter hospital stays, and rapid recovery with negligible incisions, wide product availability, and minimal adverse effects.
Aging is a significant driver of increased health care. After isolating the impact of each of the four major drivers of health spending i.e., population growth, population aging, improvements in quality of care, and inflation due to rising drug prices, physician services, hospital maintenance, and other expenses, the Conference Board estimates that population aging by itself will drive 20 percent of all health care spending growth over the next ten years.
Men are opting for cosmetic treatments such as hair restoration, cellulite removal, fat or wrinkle removal, and facial rejuvenation. This change in perception of masculine beauty can also be ascribed to men’s changing expectations in contemporary society. The aesthetic trend for men is moving toward a more youthful, toned, and bright appearance.
Based on application, the Europe hyaluronic acid-based dermal fillers market is segmented into wrinkle removal, lip augmentation, rhinoplasty, and others. The wrinkle removal segment held the largest market share of 29.5% in 2023 and is also expected to grow at the fastest CAGR of 8.3% over the forecast period. Hyaluronic acid fillers are gaining popularity in varied antiaging treatments. The increasing need and impulse to look young and defer the effects of aging have led to the advancement in technology, resulting in noninvasive procedures for the treatment of wrinkles.
Hyaluronic acid fillers are time-saving procedures that require no bandages or incisions and impose no restrictions after completion of the procedure. These act as substitutes for injectable fillers such as collagen because they are relatively less expensive, have a negligible risk of allergic reaction, and are more comfortable compared to injectable fillers.
The market in Europe can be broadly studied based on product into single-phase products and duplex products. Single-phase products accounted for around 51.0% share in 2023 and are expected to grow at the fastest CAGR over the forecast period. This is owing to technological advancements, a wide range of applications, increasing government funding for innovation, and a rise in applications of implantable devices.
Hylacross technology provides a high concentration of cross-linked hyaluronic acid molecules, resulting in the longevity of desirable effects. These are utilized for volumizing and correcting deeper folds, leading to more preferability. Desired and beneficial effects produced by single-phase products are leading to an increase in their preference among consumers.
Dermal fillers market growth has been considerably influenced by increased per capita spending on cosmetics and rising awareness of aesthetic procedures through various platforms. Personal care costs have increased due to changing human behaviors and lifestyles, rising incomes, and concern for beauty. As the population ages and people's interest in aesthetics increases, demand for dermal fillers will continue to rise. The growing popularity of aesthetic operations results from technology advancements and a wider variety of procedures being offered. Dermal fillers and other therapies and surgical and non-surgical procedures are now available to patients.
In 2023, Germany dominated the market and accounted for the largest share of 25.1% due to the rising aesthetic consciousness, quick improvements, and reduced process times. Italy has the largest geriatric population in Europe and accounts for the second-largest geriatric population worldwide.
The elderly and middle-aged women prefer antiaging treatments to enhance aesthetic appeal, whereas women prefer lip and cheek augmentation procedures in their twenties. Restylane, Perfectha, Juvederm, and Belotero are some of the popular hyaluronic acid dermal fillers in the UK.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Europe hyaluronic acid-based dermal fillers market
Product
Application
Country
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Application
1.1.3. Country scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product
2.2.2. Application
2.2.3. Country scope
2.3. Competitive Insights
Chapter 3. Europe Hyaluronic Acid-based Dermal Fillers Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Europe Hyaluronic Acid-based Dermal Fillers Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Europe Hyaluronic Acid-based Dermal Fillers Market: Product Estimates & Trend Analysis
4.1. Europe Hyaluronic Acid-based Dermal Fillers Market: Key Takeaways
4.2. Europe Hyaluronic Acid-based Dermal Fillers Market: Movement & Market Share Analysis, 2024 & 2033
4.3. Single-phase Products
4.3.1. Single-phase products market estimates and forecasts, 2021 to 2033 (USD Million)
4.4. Duplex Products
4.4.1. Duplex products market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 5. Europe Hyaluronic Acid-based Dermal Fillers Market: Application Estimates & Trend Analysis
5.1. Europe Hyaluronic Acid-based Dermal Fillers Market: Key Takeaways
5.2. Europe Hyaluronic Acid-based Dermal Fillers Market: Movement & Market Share Analysis, 2024 & 2033
5.3. Wrinkle Removal
5.3.1. Wrinkle removal market estimates and forecasts, 2021 to 2033 (USD Million)
5.4. Lip Augmentation
5.4.1. Lip augmentation market estimates and forecasts, 2021 to 2033 (USD Million)
5.5. Rhinoplasty
5.5.1. Rhinoplasty market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 6. Europe Hyaluronic Acid-based Dermal Fillers Market: Country Estimates & Trend Analysis
6.1. Europe
6.1.1. UK
6.1.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
6.1.2. Germany
6.1.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
6.1.3. France
6.1.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
6.1.4. Italy
6.1.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
6.1.5. Spain
6.1.5.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
6.1.6. Sweden
6.1.6.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
6.1.7. Norway
6.1.7.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
6.1.8. Denmark
6.1.8.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Allergan
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Galderma Laboratories
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Merz Pharma
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Genzyme corporation
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Medicis Pharmaceutical (Bausch Health)
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Inamed Corporation
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Anika Therapeutics, Inc
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Laboratoires VIVACY
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Bioxis Pharmaceuticals
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Bohus Biotech AB
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives